Health Cor Management, L.P. Abb Vie Inc. Transaction History

Health Cor Management, L.P.

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$134.21 - $153.93 $41.6 Million - $47.8 Million	310,250 New	310,250 $41.6 Million
Q2 2022 Aug 15, 2022	SELL	$137.62 - $174.96 $35 Million - $44.5 Million	-254,160 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$131.98 - $163.75 $17 Million - $21.1 Million	129,010 Added 103.08%	254,160 $41.2 Million
Q4 2021 Feb 14, 2022	BUY	$107.43 - $135.93 $13.4 Million - $17 Million	125,150 New	125,150 $16.9 Million
Q2 2021 Aug 16, 2021	SELL	$105.21 - $117.21 $76.7 Million - $85.5 Million	-729,420 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$102.3 - $112.62 $12.7 Million - $14 Million	-124,230 Reduced 14.55%	729,420 $78.9 Million
Q4 2020 Feb 16, 2021	SELL	$80.49 - $108.67 $37.4 Million - $50.6 Million	-465,250 Reduced 35.28%	853,650 $91.5 Million
Q3 2020 Nov 16, 2020	BUY	$85.91 - $100.83 $114,260 - $134,103	1,330 Added 0.1%	1,318,900 $116 Million
Q2 2020 Aug 14, 2020	BUY	$73.37 - $98.18 $62.6 Million - $83.8 Million	853,670 Added 184.02%	1,317,570 $129 Million
Q1 2020 May 15, 2020	BUY	$64.5 - $97.79 $29.9 Million - $45.4 Million	463,900 New	463,900 $35.3 Million
Q2 2018 Aug 14, 2018	SELL	$89.78 - $106.23 $51.5 Million - $61 Million	-574,070 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$92.01 - $123.21 $16.1 Million - $21.6 Million	-175,340 Reduced 23.4%	574,070 $54.3 Million
Q4 2017 Feb 14, 2018	SELL	$89.56 - $98.21 $21.2 Million - $23.3 Million	-236,910 Reduced 24.02%	749,410 $72.5 Million
Q3 2017 Nov 14, 2017	BUY	$69.85 - $89.22 $68.9 Million - $88 Million	986,320	986,320 $87.6 Million

3,863

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $299B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Health Cor Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Health Cor Management, L.P. with notifications on news.